Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report

Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report

Abstract Background Regorafenib is an oral multikinase inhibitor that has been demonstrated as clinically effective in patients with metastatic colorectal cancer in phase III studies. Although disease control was achieved in 40% of the pretreated patients with metastatic colorectal cancer in the piv...

Full description

Bibliographic Details
Main Authors: Kenji Yoshino, Dai Manaka, Ryo Kudo, Shunpei Kanai, Eisei Mitsuoka, Satoshi Kanto, Shinya Hamasu, Sayuri Konishi, Ryuta Nishitai
Format: Article
Language:English
Published: BMC 2017-08-01
Series:Journal of Medical Case Reports
Subjects:
Colorectal cancer
Regorafenib
Lymph node metastasis
Partial response
Online Access:http://link.springer.com/article/10.1186/s13256-017-1366-4

Internet

http://link.springer.com/article/10.1186/s13256-017-1366-4

Similar Items